Latest publications

Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry. Boesjes CM, Kamphuis E, Zuithoff NPA, Bakker DS, Loman L, Spekhorst LS et al. Acta Derm Venereol 2022 Nov 24; 102:adv00820

Dupilumab has a profound effect on specific-IgE levels of several food allergens in atopic dermatitis patients. Spekhorst LS, Van de Rijst LP, De Graaf M, Van Megen M, Zuithoff NPA, Knulst AC et al. Allergy 2022 Nov 24

A meta-analysis of methotrexate polyglutamates in relation to efficacy and toxicity of methotrexate in inflammatory arthritis, colitis and dermatitis. Van de Meeberg MM, Hebing RCF, Nurmohamed MT, Fidder HH, Heymans MW, Bouma G et al. Br J Clin Pharmacol 2022 Nov 03

Association of Serum Dupilumab Levels at 16 Weeks With Treatment Response and Adverse Effects in Patients With Atopic Dermatitis: A Prospective Clinical Cohort Study From the BioDay Registry. Spekhorst LS, De Graaf M, Loeff F, Zuithoff NPA, Bakker D, Boesjes CM et al. JAMA Dermatol 2022 Nov 02

Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials. Simpson EL, Merola JF, Silverberg JI, Reich K, Warren RB, Staumont-Sallé D et al. Br J Dermatol 2022 Sep 09

Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry. Spekhorst LS, De Graaf M, Zuithoff NPA, Van den Reek JMPA, Kamsteeg M, Boesjes CM et al. JAMA Dermatol 2022 Sep 01; 158(9):1048-1056

Drug Survival, Safety, and Effectiveness of Biologics in Older Patients with Psoriasis: A Comparison with Younger Patients-A BioCAPTURE Registry Study. Ter Haar ELM, Thomas SE, Van den Reek JMPA, Otero ME, Njoo MD, Ossenkoppele PM et al. Drugs Aging 2022 Sep; 39(9):715-727

Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis. Spekhorst LS, Bakker D, Drylewicz J, Rispens T, Loeff F, Boesjes CM et al. Allergy 2022 Nov; 77(11):3398-3407

Recombinant human C1 esterase inhibitor as prophylactic treatment in idiopathic non-histaminergic angioedema. Alizadeh Aghdam M, Hofman ZLM, Meertens M, Lebens A, Hack CE, Knulst AC et al. Allergy 2022 Jul 15

Systemic treatment of children and adolescents with atopic dermatitis aged ≥2 years: a Delphi consensus project mapping expert opinion in Northern Europe. De Graaf M, Janmohamed SR, Schuttelaar MLA, Agner T, Alfonso JH, De Schepper S et al. J Eur Acad Dermatol Venereol 2022 Nov; 36(11):2153-2165

Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis. De Bruin-Weller MS, Serra-Baldrich E, Barbarot S, Grond S, Schuster C, Petto H et al. Dermatol Ther (Heidelb) 2022 Jun; 12(6):1481-1491

Aesthetic Outcome of Propranolol vs Atenolol Treatment of Children with Infantile Haemangioma. Hermans MM, Breugem CC, Schappin R, Jonge Poerink E, Mendels EJ, Ragamin A et al. Acta Derm Venereol 2022 Oct 11; 102:adv00788

Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. Beck LA, Deleuran M, Bissonnette R, De Bruin-Weller M, Galus R, Nakahara T et al. Am J Clin Dermatol 2022 May; 23(3):393-408

Estimating the Risk of Severe Peanut Allergy Using Clinical Background and IgE Sensitization Profiles. Datema MR, Lyons SA, Fernández-Rivas M, Ballmer-Weber B, Knulst AC, Asero R et al. Front Allergy 2021; 2:670789

Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort. Van Muijen ME, Thomas SE, Groenewoud HMM, Otero ME, Ossenkoppele PM, Njoo MD et al. Acta Derm Venereol 2022 May 16; 102:adv00712